Background
Unruptured intracranial aneurysms are abnormal bulges in the wall of a brain artery. They are often found by chance during imaging for another reason, and many never rupture. However, when an aneurysm does burst, it can cause subarachnoid hemorrhage, a life-threatening type of bleeding around the brain. Depending on the location and size of the aneurysm, rupture can also be accompanied by bleeding into the brain tissue itself or into the ventricles, worsening outcomes.
Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, are medications widely used for diabetes and, more recently, weight management. Common examples include semaglutide, liraglutide, dulaglutide, and tirzepatide-related incretin therapies, although tirzepatide is a dual GIP/GLP-1 agonist rather than a pure GLP-1RA. These drugs are known not only for lowering blood glucose and supporting weight loss, but also for anti-inflammatory and vascular protective effects. Because inflammation and vessel-wall instability are thought to contribute to aneurysm growth and rupture, researchers have begun to ask whether GLP-1RAs might also help stabilize aneurysms or reduce the severity of a rupture if one occurs.
This study examined that question using a large real-world health record network in the United States.
Study design
The investigators performed a retrospective cohort study using the TriNetX US Collaborative Network, covering data from 2016 to 2024. Two separate patient groups were analyzed.
The first group included patients with newly diagnosed, untreated unruptured intracranial aneurysms. In this group, the main question was whether prior or recent GLP-1RA use was linked to a lower chance of aneurysm rupture over time.
The second group included patients who experienced aneurysm rupture. In this group, the researchers examined whether GLP-1RA use before the rupture was associated with milder bleeding severity, fewer complications such as vasospasm, and lower short-term mortality.
To make the groups more comparable, the team used propensity score matching. This statistical method helps balance important characteristics such as age, sex, comorbid conditions, and medication use, reducing some of the bias that can occur in observational studies. Even so, this type of study cannot prove causation in the same way as a randomized clinical trial.
How GLP-1RA exposure was defined
For the unruptured aneurysm cohort, GLP-1RA use meant that a patient had been prescribed a GLP-1 receptor agonist before, or within three months after, the diagnosis of the aneurysm.
For the rupture cohort, exposure meant the patient had used a GLP-1RA before the rupture event. This approach focused on whether medication exposure might have influenced aneurysm stability or the consequences of rupture.
Main findings in patients with unruptured aneurysm
After matching, the first cohort included 8,088 GLP-1RA users and 8,088 nonusers with untreated unruptured intracranial aneurysms.
GLP-1RA use was associated with a significantly lower risk of rupture at multiple time points:
1-year risk: 0.65% in GLP-1RA users versus 1.51% in nonusers
3-year risk: 1.18% versus 1.85%
5-year risk: 1.49% versus 2.10%
Across the full follow-up period, GLP-1RA use was associated with a 48% reduction in hazard of rupture, with a hazard ratio of 0.52 and a 95% confidence interval of 0.38 to 0.69.
In practical terms, this means that patients who had received GLP-1RAs appeared less likely to experience aneurysm rupture than similar patients who had not used these drugs. The difference was not huge in absolute terms, but it was consistent and statistically significant.
Main findings in patients who experienced rupture
The second cohort included 298 matched patients after propensity score balancing, with 149 GLP-1RA users and 149 nonusers.
Among patients whose aneurysm ruptured, prior GLP-1RA use was associated with less severe bleeding patterns and fewer complications:
Intraparenchymal hemorrhage: 17.4% in GLP-1RA users versus 33.6% in nonusers
Intraventricular hemorrhage: 10.1% versus 23.5%
Clinically significant vasospasm: 10.7% versus 24.2%
30-day mortality: 9.4% versus 14.1%, although this difference did not reach statistical significance
These results suggest that patients exposed to GLP-1RAs before rupture may have had a somewhat less severe clinical course. The lower rates of intraparenchymal hemorrhage and intraventricular hemorrhage are especially notable, because these forms of bleeding often signal a more complicated and dangerous event.
Vasospasm, a narrowing of brain arteries that can occur after subarachnoid hemorrhage, is a major cause of delayed ischemic injury and poor outcomes. The lower vasospasm rate in GLP-1RA users is therefore clinically meaningful, even though the study was not designed to prove a mechanism.
Why might GLP-1RAs help?
The exact biological explanation remains uncertain, but there are several plausible mechanisms. GLP-1RAs have been associated with reduced systemic inflammation, improved endothelial function, better blood vessel health, and favorable effects on oxidative stress and metabolic regulation. In aneurysm disease, chronic inflammation in the vessel wall and degenerative changes in the arterial structure are believed to contribute to growth and rupture. A drug class that reduces inflammation and supports vascular stability could, in theory, lower the chance of rupture.
Another possible explanation is indirect benefit through improved control of diabetes, obesity, and cardiovascular risk factors, which may influence overall vascular health. However, the study design cannot separate direct drug effects from the broader health patterns seen in people who are prescribed GLP-1RAs.
Clinical meaning
These findings are promising because there are currently no medications specifically approved to prevent rupture of unruptured intracranial aneurysms. Standard management usually depends on aneurysm size, location, shape, patient age, smoking status, blood pressure control, and overall rupture risk. Some aneurysms are monitored with serial imaging, while others are treated with clipping or endovascular procedures such as coiling or flow diversion.
If future studies confirm these results, GLP-1RAs could become part of a broader strategy to reduce aneurysm-related risk in selected patients, especially those already taking these agents for diabetes or obesity. Still, this does not mean GLP-1RAs should be started solely for aneurysm prevention at this stage. The evidence is observational, and treatment decisions should continue to be based on established aneurysm guidelines and individual risk assessment.
Important limitations
As with any retrospective database study, several limitations should be considered. First, medication exposure was based on recorded prescriptions, not guaranteed actual use. Second, residual confounding may remain even after matching; for example, patients prescribed GLP-1RAs may differ from nonusers in ways that are difficult to fully measure, such as access to care, weight trends, or adherence to other preventive treatments.
Third, the study did not provide detailed aneurysm characteristics such as exact aneurysm size, shape, or location for every patient, which are key determinants of rupture risk. Fourth, the findings are from a U.S. health record network and may not generalize perfectly to other populations or healthcare systems. Fifth, the lower mortality seen in the rupture cohort did not reach statistical significance, so it should be interpreted cautiously.
Finally, observational studies can show association, but they cannot prove that GLP-1RAs directly caused the lower rupture risk or milder hemorrhage severity. Randomized trials are unlikely to be practical for this specific question, but prospective studies and mechanistic research would be valuable.
Bottom line
In this large real-world analysis, GLP-1 receptor agonist use was associated with a lower risk of rupture in patients with untreated unruptured intracranial aneurysms. Among patients who did rupture, prior GLP-1RA use was linked to less severe hemorrhagic features and less clinically significant vasospasm.
The results raise an important possibility: GLP-1RAs may have neurovascular protective effects beyond their established roles in diabetes and obesity care. For now, these findings should be seen as hypothesis-generating rather than practice-changing. They do, however, open an exciting new line of research into whether commonly used metabolic medications can also help stabilize vulnerable brain blood vessels.
